Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Tue, 22.12.2020
Polyphor AG
Allschwil, Switzerland, December 22, 2020
Polyphor receives approval to start first-in-human clinical trial of inhaled antibiotic murepavadin
- Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the U [ … ]
Mon, 14.12.2020
Polyphor AG
Allschwil, Switzerland, December 14, 2020
Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications
Polyphor AG (SIX: POLN) announced today that the clinical trial independent Data Safety Monitoring Board (DSMB) has completed the third, pre-specifi [ … ]
Fri, 11.12.2020
Polyphor AG
Allschwil, Switzerland, December 11, 2020
Polyphor receives an additional USD 2.3 million award from CARB-X to support ongoing development of a new class of antibiotics targeting multi-drug resistant Gram-negative pathogens
Polyphor AG (SIX: POLN) today announced the extension of its existing grant agreement with CARB-X (Combating Antibiotic-Resi [ … ]
Tue, 24.11.2020
Polyphor AG
Allschwil, Switzerland, November 24, 2020
Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin
- Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infec [ … ]
Fri, 13.11.2020
Polyphor AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE US
Polyphor to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Treatment of HER2 Negative Metastatic Breast Cancer
Webinar to Take Place Friday, November 20, 2020 @ 4pm Central European Time (CET)
Allschwil, Switzerland, November 13, 2020 - Polyphor AG (SIX: POLN) [ … ]
Thu, 29.10.2020
Polyphor AG
Allschwil, Switzerland, October 29, 2020
Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
Polyphor AG (SIX: POLN) today announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic breast cancer. A total of 411 patients have been recruited, including 323 i [ … ]
Wed, 14.10.2020
Polyphor AG
Allschwil, Switzerland, October 14, 2020
Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program
Polyphor AG (SIX: POLN), announced today that it has received a new and second non-dilutive funding award from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global [ … ]
Tue, 29.09.2020
Polyphor AG
Allschwil, Switzerland, September 29, 2020
Polyphor announces closing of Fosun Pharma licensing agreement for balixafortide in China and receipt of $15 million upfront payment
Polyphor AG (SIX: POLN) today announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China. As a result of c [ … ]
Fri, 11.09.2020
Polyphor AG
Allschwil, Switzerland, September 11, 2020
Polyphor to present at the H.C. Wainwright Global Investment Conference
Polyphor AG (SIX: POLN) today announced that the company will present at the 22st Annual H.C. Wainwright Global Investment Conference, taking place September 14 -16, 2020 (Virtual Conference). Gokhan Batur, CEO of Polyphor, will prov [ … ]
Thu, 03.09.2020
Polyphor AG
Allschwil, Switzerland, September 3, 2020
Polyphor announces financial results for the first half 2020
- Strong progress in Phase III balixafortide trial despite COVID-19; enrollment completion expected in the coming weeks
- Exclusive licensing agreement for balixafortide in China with Fosun Pharma
- Preparing to initiate Phase I study of inh [ … ]